https://www.avient.com/investor-center/news/avient-completes-sale-distribution-business-hig-capital
November 2, 2022
Great Place
They are based on management's expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements.
https://www.avient.com/sites/default/files/2022-01/Avient S.à r.l._extract CoC_2021.12.27.pdf
titel 20 21 -1 2- 27 1 1: 24 :4 8 Business Register extract Netherlands Chamber of Commerce CCI number 72287497 Page 1 (of 2) Legal entity RSIN 859060317 Legal form Foreign Legal Entity: Société à Responsabilité Limitée (S.A.R.L.)
Corporate seat Luxemburg Date of deed of incorporation 04-07-2018 Registered in Registre de Commerce et des sociétés Luxemburg, Luxembourg under number B226205 Company Trade name Avient S.à r.l., Netherlands branch Company start date 24-07-2018 Activities SBI-code: 46769 - Wholesale of other intermediary products SBI-code: 46696 - Wholesale of packaging SBI-code: 4941 - Freight transport by road (no removal services) Employees 0 Establishment Establishment number 000040405362 Trade name Avient S.à r.l., Netherlands branch Visiting address Uranusweg 3, 8938AJ Leeuwarden Date of incorporation 24-07-2018 Activities SBI-code: 46769 - Wholesale of other intermediary products SBI-code: 46696 - Wholesale of packaging SBI-code: 4941 - Freight transport by road (no removal services) For further information on activities, see Dutch extract.
Business Register extract Netherlands Chamber of Commerce CCI number 72287497 Page 2 (of 2) N/A 2021-12-27T11:24:54+0100 Utrecht Kamer van Koophandel Dit document is digitaal ondertekend 2021-12-27T11:24:55+0100
https://www.avient.com/sites/default/files/2024-12/Terms and Conditions of Sale for France.pdf
Furthermore, the parties agree that Seller’s performance under these Terms shall not be an acceptance of any of Buyer’s terms and conditions. 2.
The Products are supplied at the price in force at the time the order is placed as identified on Seller’s order confirmation, expressed in euros and taking into account the applicable VAT on the day the order is placed; any change in the rate may be reflected in the price of the products.
Unless otherwise agreed, prices are net, excluding transport and taxes, on the basis of the rates communicated to Buyer on the date the order is placed. 4.
https://www.avient.com/after-fx-post-press-special-effects
The most common post-surface manipulation is called “tapping”—the practice of placing a Teflon sheet over a cured print and hitting it with a transfer machine.
To achieve different textures and finishes, a number of materials can be used in place of Teflon to yield great results.
https://www.avient.com/sites/default/files/2025-01/Glasforms Dowel Bar Application Overview.pdf
When concrete slabs expand or contract due to temperature changes or traffic loads, dowel bars placed across the transverse joints between slabs help distribute the weight and reduce the risk of cracking.
Matrix Resin Fiber Reinforcement Fiber Content, by Weight (%) Epoxy E-CR or E-Glass >70% MATERIAL TECHNICAL DATA Property Test Procedure Rod Diameter 1.25 in (31.75 mm) 1.50 in (38.10 mm) Glass Transition Temp (Tg) ASTM 1356 100°C Minimum 100°C Minimum Water Absorption 24 hours at 50°C (122°F) ASTM D570 0.03% 0.03% Short Beam Strength (ILSS) ASTM 2344 8,400 psi (58 MPa) 9,200 psi (64 MPa) Transverse Shear Strength ASTM 7617 23,400 psi (160 MPa) 24,640 psi (170 MPa) Traceability Lot number shall be clearly marked on each package/shipment.
https://www.avient.com/sites/default/files/2023-01/Mevopur Healthcare Functional Additives_Laser Welding Additives for Medical Devices Application Bulletin.pdf
KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number, reducing risk of change • Available as additive concentrates, ready-to-use additive formulations or ready-to-use additive/ colorant formulations for different polymers REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request; exceptions may occur Healthcare use limitations apply—see below.
It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.
https://www.avient.com/sites/default/files/2021-01/avient-colorants-sweden-ab-certificate-of-registration.pdf
e-Certificate of registration Swedish Companies Registration Office LIMITED COMPANY D1a- 6064988 Registration number Date of registration of the company Document created on Date of registration of current name Page 556393-1020 1990-04-10 2020-11-30 14:53 2020-11-30 1 (2) Registration number: 556393-1020 Business name: Avient Colorants Sweden AB Address: Box 9053 200 39 MALMÖ Registered office: Malmö Note: The company is registered as a private limited company.
THE COMPANY WAS FORMED 1990-03-29 SHARE CAPITAL Share capital...: SEK 3,200,000 Min.............: SEK 3,000,000 Max.............: SEK 12,000,000 Number of shares: 32,000 Min.............: 30,000 Max.............: 120,000 BOARD MEMBER, MANAGING DIRECTOR 660613-3954 Nilsson, Bo Patrik Joakim, Hovslagaregatan 13, 271 57 YSTAD BOARD MEMBER, CHAIR OF THE BOARD 640503 Merklein, Norbert, Fichtenstrasse 20, 61476 KRONBERG IM TAUNUS, TYSKLAND BOARD MEMBERS 750618-4089 Norén, Jenny Eva Kristina, Fårabäcksvägen 68, 212 91 MALMÖ 610322 Smeds, Jan-Håkan, Chämiweg 23, NEFTENBACH, TYSKLAND AUDITORS 556029-6740 Öhrlings PricewaterhouseCoopers AB, Box 4009, 203 11 MALMÖ Represented by: 710921-4689 PRINCIPALLY RESPONSIBLE AUDITOR 710921-4689 Olsson, Karin Maria, c/o PwC, 405 32 GÖTEBORG SIGNATORY POWER e-Certificate of registration Swedish Companies Registration Office LIMITED COMPANY D1a- 6064988 Registration number Date of registration of the company Document created on Date of registration of current name Page 556393-1020 1990-04-10 2020-11-30 14:53 2020-11-30 2 (2) The board of directors is entitled to sign.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Bio-based Polymer Solutions Application Bulletin.pdf
KEY CHARACTERISTICS • Available for polyethylene, polypropylene, ABS, polycarbonate and styrenics • Bio-content of resin carrier varies from 70% to 100% depending on polymer—calculated to ASTM D6866 standard • Manufactured at four ISO 13485 certified sites, providing global consistency and security of supply • Documented change control beyond CAS number, reducing risk of change • Drop-in solutions that can be processed like fossil-based grades on common injection molding and extrusion machines • Can be provided as ready-to-use pre-colored or additive formulation REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP and (incl. class VI) - European Pharmacopeia, monograph 3.1.3/ 3.1.5 (polyolefin packaging materials) - USP (polyethylene) - Elemental impurities as per ICH Q3D • Registered Drug Master File (Type III) and/or Device Master File • Food contact according to US FDA and APPLICATION BULLETIN Sustainability Spotlight Bio-polymers Healthcare use limitations apply—see below.
It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.
https://www.avient.com/sites/default/files/2023-03/Mevopur Healthcare Functional Additives Nucleating Application Bulletin.pdf
REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.
It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.
https://www.avient.com/sites/default/files/2023-05/Mevopur Healthcare Colorants and Formulations Amber for Pharma Application Bulletin.pdf
KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.
It is the responsibility of the medical device manufacturer and the person placing the medical device on the market to ensure compliance of the medical device with all applicable laws and regulations, including the suitability of all raw materials and components used for its manufacture.